Points for Consideration for dengue vaccine introduction - Recommendations by the Dengue Vaccine Initiative

Expert Review of Vaccines

Volumn 15, Issue 4, 2016, Pages 529-538

  Lim, Jacqueline Kyungah ^a   Lee, Yong Seok ^a   Wilder Smith, Annelies ^b   Thiry, Georges ^c   Mahoney, Richard ^d   Yoon, In Kyu ^a  

^a International Vaccine Institute   (South Korea)

^b LEE KONG CHIAN SCHOOL OF MEDICINE   (Singapore)

^c Senergues Consult   (France)

^d RTM Asociates   (United States)

Author keywords

Dengue; Dengue Vaccine Initiative; introduction; points for consideration; vaccine

Indexed keywords

DENGUE VACCINE;

CLINICAL EFFECTIVENESS; DECISION MAKING; DENGUE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED PRACTICE; GENOTYPE; HUMAN; IMMUNITY; ORGANIZATION AND MANAGEMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SEROTYPE; VACCINATION; VIRUS INTERFERENCE; DISEASE TRANSMISSION; HEALTH CARE POLICY; IMMUNOLOGY; ISOLATION AND PURIFICATION; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; UTILIZATION;

DECISION MAKING; DENGUE; DENGUE VACCINES; DISEASE TRANSMISSION, INFECTIOUS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; VACCINATION;

EID: 84953277629     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1129279     Document Type: Review

References (30)

1. Mahoney R. The introduction of new vaccines into developing countries. V: will we lose a decade or more in the introduction of dengue vaccines to developing countries? Vaccine. 2014; 32 (8): 904-908.
2. Hajjeh RA, Privor-Dumm L, Edmond K., et al. Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine. 2010; 28 (43): 7123-7129.
3. Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013; 5: 299-309.
4. Thomas SJ. Preventing dengue-is the possibility now a reality? N Engl J Med. 2015; 372 (2): 172-173.
5. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011; 24 (5): 442-450.
6. Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014; 384 (9951): 1327-1329.
7. Wilder-Smith A, Macary P. Dengue: challenges for policy makers and vaccine developers. Curr Infect Dis Rep. 2014; 16 (5): 404.
8. Ramakrishnan L, Pillai MR, Nair RR. Dengue vaccine development: strategies and challenges. Viral Immunol. 2015; 28 (2): 76-84.
9. Sariol CA, White L. Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front Immunol. 2014; 5 (452).
10. Wallace D, Canouet V, Garbes P., et al. Challenges in the clinical development of a dengue vaccine. Curr Opin Virol. 2013; 3 (3): 352-356.
11. APDPB, DVI. Points for consideration for first introductions of Dengue Vaccines-the DVI Asia-Pacific Dengue Prevention Board meeting. Dengue Vaccine Initiative; 2012.
12. AmDPB, DVI. Points for Consideration for First Introductions of Dengue Vaccines-the DVI Americas Dengue Prevention Board meeting. Dengue Vaccine Initiative; 2012.
13. Sabchareon A, W D, Sirivichayakul C., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012; 380 (9853): 1559-1567.
14. Arya V. An effective dengue vaccine: a glass half full or half empty? Natl Med J India. 2013; 26 (1): 38-39.
15. Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Burke D., et al. Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis. 2013; 7 (8): e2126.
16. Capeding MR, Tran N, Hadinegoro SR, et al. CYD14 study group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet (London, England). 2014; 384 (9951): 1358-1365.
17. Villar L, Rivera-Medina D, Arredondo-García JL., et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013; 32 (10): 1102-1109.
18. APDPB, DVI. Development of dengue vaccines-a review of the status and future considerations, the DVI Asia-Pacific Dengue Prevention Board meeting. Dengue Vaccine Initiative; 2014.
19. AmDPB, DVI. Development of dengue vaccines-a review of the status and future considerations,-the DVI Americas Dengue Prevention Board meeting. Dengue Vaccine Initiative; 2015.
20. Torresi J, Tapia-Conyer R, Margolis H. Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting. PLoS Negl Trop Dis. 2013; 7 (9): e2261.
21. Thisyakorn U, Capeding MR, Goh DY., et al. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Rev Vaccines. 2014; 13 (5): 581-587.
22. Tapia-Conyer R, Betancourt-Cravioto M, Saucedo-Martinez R., et al. Strengthening vaccination policies in Latin America: an evidence-based approach. Vaccine. 2013; 31 (37): 3826-3833.
23. Edelman R, Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization Technical Consultation. Vaccine. 2008; 26 (33): 4113-4119.
24. Lam SK, Burke D, Capeding MR., et al. Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine. 2011; 29 (51): 9417-9422.
25. Hajjeh R. Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience. Philos Trans R Soc Lond B Biol Sci. 2011; 366 (1579): 2827-2832.
26. Hyde TB, Dentz H, Wang SA., et al. The impact of new vaccine introduction on immunization and health systems: a review of the published literature. Vaccine. 2012; 30 (45): 6347-6358.
27. Hombach J. Guidelines for clinical trials of dengue vaccine in endemic areas. J Clin Virol. 2009; 46 (Suppl 2): S7-9.
28. Live Dengue Vaccines Technical Consultation Reporting Group1 B-EA, Schmitz J, Edelman R, Durbin A., et al. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine. 2013; 31 (23): 2603-2609.
29. Douglas DL, DeRoeck DA, Mahoney RT., et al. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. PLoS Negl Trop Dis. 2013; 7 (3): e2127.
30. Thiry GHJ, Constenla D, Carvalho A., et al. New chapter unfolding in the fight against dengue with an unwritten ending. Trans R Soc Trop Med Hyg. 2014; 108 (10): 597-598.